ArticleBlood research2026
G6PD activity patterns and a stable adjusted male median derived from 16 years of clinical laboratory data.
Article in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlucose-6-phosphate dehydrogenase (G6PD) deficiency, the most common enzymopathy worldwide, poses significant clinical and public health challenges, particularly in malaria-endemic regions. Despite the importance of quantitative G6PD activity assessments, clinically meaningful deficiency thresholds remain difficult to define owing to biological variability related to age, sex, and X-linked inheritance. The adjusted male median (AMM) is a recommended framework for defining 100% activity and deriving assay- and region-specific thresholds. However, large-scale evaluations of AMM stability and G6PD activity patterns in Pakistan are limited.
methodsWe retrospectively analyzed all quantitative G6PD assays performed at a national reference laboratory in Pakistan between January 2009 and December 2024. Records with valid G6PD activity (U/g hemoglobin (Hb)), age, and sex information were included. Age- and sex-stratified distributions were examined across predefined clinical age groups. The calculated AMM was based on adult males aged 18-45 years (excluding those with ≤ 10% of the initial median). Sensitivity analyses were used to assess AMM stability across alternative adult male age windows (15-50 and 18-60 years). The G6PD activity categories were defined as severe (< 10%), moderate (10-30%), intermediate (30-60%), and normal (> 60%) relative to the AMM.
resultsIn total, 51,748 specimens (41,397 from males and 10,351 from females) were analyzed. The median (interquartile range) G6PD activity was 10.3 (7.8-12.6) U/g Hb among males and 10.7 (8.5-12.9) U/g Hb among females. The AMM derived from 7,436 adult males was 9.2 U/g Hb and remained highly stable across alternative age windows (9.2-9.3 U/g Hb; ~ 1% variation). Based on AMM thresholds, 15.4% (95% CI: 15.1-15.7%) of the tested population had < 60% activity, including 6.8% with severe and 4.9% with moderate deficiency. G6PD activity was highest in neonates and infants and declined progressively with age.
conclusionsThe locally derived AMM provides a robust reference standard that reflects the enzymatic capacity within the specific clinical catchment area and serves as a foundation for future clinical validation studies. Age- and sex-specific activity patterns aligned with known physiological and genetic determinants. Although this study provided a locally validated laboratory reference framework, prospective studies correlating the enzymatic categories with clinical outcomes and genotypic data are needed before its broader clinical or public health implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.